Ultra low-dose hormone replacement therapy and bone protection in postmenopausal women.

Ultra low-dose hormone replacement therapy and bone protection in postmenopausal women. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Ultra low-dose hormone replacement therapy and bone protection in postmenopausal women. Abstract Text:

Marco Gambacciani,Barbara Cappagli,Massimo Ciaponi,Antonia Pepe,Francesca Vacca,Andrea Riccardo Genazzani,

OBJECTIVES: The aim of the present study was to evaluate the effects of low doses of hormone replacement therapy (HRT) in normal young postmenopausal women. METHODS: In an open trial healthy, non-obese postmenopausal women received for 2 years a low-dose continuous combined HRT (LD-HRT) containing 1mg estradiol+0.5mg norethisterone acetate each pill for 28 days, or 0.5mg of 17beta-estradiol and 0.25mg of norethisterone acetate (Ultra low dose, Ultra-LD-HRT) along with 1000mg of calcium per day. Control group consisted of women receiving only 1000mg of calcium per day, for 2 years. Menopausal symptoms were evaluated by the Green climacteric scale for the first 12 weeks of the study while bleeding profiles, bone mineral density (BMD) and bone turnover were assessed for 24 months. RESULTS: LD-HRT and Ultra-LD-HRT were effective in reducing menopausal clinical symptoms. In the control group, BMD significantly (P<0.05) decreased at the spine (-2.8+/-0.2%), and femoral neck (-2.8+/-0.7%). In LD-HRT treated group BMD showed a significant (P<0.05) increase at the spine (5.2+/-0.7%), and femoral neck (2.8+/-0.4%) after 24 months. In the Ultra-LD-HRT treated women spine and femoral neck BMD showed a significant (P<0.05) increase (2.0+/-0.3 and 1.8+/-0.3%, respectively) after 24 months. In these women treated with LD-HRT and Ultra-LD-HRT the BMD values were significantly (P<0.05) different from those measured in calcium-treated women. CONCLUSIONS: LD-HRT and Ultra-LD-HRT can alleviate subjective symptoms providing an effective protection against the postmenopausal decrease of BMD.

Ultra low-dose hormone replacement therapy and bone protection in postmenopausal women. Publishing Authors By Initials

M Gambacciani,B Cappagli,M Ciaponi,A Pepe,F Vacca,AR Genazzani,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Ultra low-dose hormone replacement therapy and bone protection in postmenopausal women. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Maturitas

VOLUME: 59

Page Numbers: 2-6

Journal Abbreviation:

ISSN: 0378-5122

DAY: 3

MONTH: 12

YEAR: 2007

Ultra low-dose hormone replacement therapy and bone protection in postmenopausal women. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7807333

Ultra low-dose hormone replacement therapy and bone protection in postmenopausal women. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Ultra low-dose hormone replacement therapy and bone protection in postmenopausal women. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Ultra low-dose hormone replacement therapy and bone protection in postmenopausal women.

AFFILIATION: Department of Obstetrics and Gynecology, Pisa University Hospital, Pisa, Italy.

Country: Ireland

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Maturitas

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Ultra low-dose hormone replacement therapy and bone protection in postmenopausal women Related Publications

• 5-hydroxytryptamine(1B) receptor and triptan response in migraine, lack of association with common polymorphisms.
• A case of acro-cephalo-syndactylia [Hebrew text].
• Biochemical prognostic factors and risk of relapses in patients with cervical cancer.
• Brain derived neurotrophic factor circulating levels in patients undergoing IVF.
• Brain recurrences in patients with ovarian cancer: report of 12 cases and review of the literature.
• CSF beta-EP in headache and depression.
• Calcineurin primes immature gonadotropin-releasing hormone-secreting neuroendocrine cells for migration.
• Characterization of NAD Uptake in Mammalian Cells.
• Circadian variations of proopiocortin-related peptides in children with migraine.
• Click chemistry reactions in medicinal chemistry: Applications of the 1,3-dipolar cycloaddition between azides and alkynes.
• Comparative effects of dydrogesterone and medroxyprogesterone acetate in critical areas: The brain and the vessels.
• Correlation of recurrence rates and times with posttreatment human papillomavirus status in patients treated with loop electrosurgical excision procedure conization for cervical squamous intraepithelial lesions.
• Effect of an oral contraceptive containing 30 microg ethinylestradiol plus 3 mg drospirenone on body composition of young women affected by premenstrual syndrome with symptoms of water retention.
• Endogenous opioid inhibitory tone on LH secretion in normal puberty and in several pubertal disturbances.
• Endorphin patterns within the headache spectrum disorders.
• Evaluation of central opioid tonus in menstrual migraine.
• Functional hypothalamic amenorrhea: Current view on neuroendocrine aberrations.
• Involvement of serotonin in the central control of opioid secretion.
• Naloxone test in primary headache sufferers.
• Neuroendocrine effects of flunarizine treatment in postmenopausal women.
• Opioid control of the hypothalamus-pituitary-adrenal axis cyclically fails in menstrual migraine.
• P26.08: Bilateral hemorrhagic fetal ovarian cyst: a case report.
• P26.12: Prenatal sonographic features of chloride diarrhea.
• Primary headaches: reduced circulating beta-lipotropin and beta-endorphin levels with impaired reactivity to acupuncture.
• Reduced testosterone levels in cluster headache: a stress-related phenomenon?
• Sympathergic/neuroendocrine reactivity as a marker of adaptive processes underlying migraine susceptibility.
• The association of menstrual migraine with the premenstrual syndrome.
• The management of patients with uterine sarcoma: A debated clinical challenge.
• The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: A review of the literature.
• Ultra low-dose hormone replacement therapy and bone protection in postmenopausal women.